Hydrocephalus in Surgically Treated Glioblastoma Patients – To Treat or Not to Treat?

Résumé fourni par la source

BACKGROUND: Due to overall poor prognosis in glioblastoma (GB) patients, the decision whether and how to treat hydrocephalus is challenging. The aim of this study is to analyze the indication and decision-making, as well as functional outcome and overall survival of GB patients treated for hydrocephalus. METHODS: We retrospectively analyzed patients who underwent surgery for GB between October 2009 and October 2023 at our department. The indication for treatment and treatment method were recorded. Further, patient and tumor characteristics, radiologic features, overall survival, as well as functional outcome based on the modified Rankin scale und Karnofsky index were assessed and compared between treated and the nontreated group. RESULTS: Out of the 781 GB patients, we identified 28 patients (3.6%) who developed hydrocephalus during treatment. Overall, 13 (46%) patients received no treatment, and 15 (54%) patients received treatment for hydrocephalus. Hereof, 9 (60%) patients were treated with ventriculoperitoneal shunt, 3 (20%) with endoscopic procedures, 2 (13.3%) with external ventricular drainage, and one (6.6%) with hematoma evacuation. Mean modified Rankin scale significantly improved after treatment of hydrocephalus (from 4 ± 1 to 3 ± 1, P = 0.005). In 88% of the cases, hydrocephalus treatment led to an improvement of the symptoms. In 3 patients (20%), complications occurred after surgical treatment of hydrocephalus. Hydrocephalus treatment prolonged survival by 102 days (98 days [interquartile range, 34; 201] vs. 200 days [interquartile range, 45; 501]) without statistically significant difference. CONCLUSIONS: The decision to treat hydrocephalus in GB patients depends on various factors and remains challenging. Treatment in patients with good functional status before hydrocephalus seems to prolong overall survival, leads to a relief in symptoms, and improves functional outcome with an acceptable risk of morbidity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.